Program
lurbinectedin
Also written as “Lurbinectedin”, “lurbinectedin (PM01183)” and “Lurbinectedin (PM01183)”.
Its studies are mostly in Small Cell Lung Carcinoma · Breast Neoplasms · Neoplasms · Sarcoma, Ewing · Leiomyosarcoma, led by 5 companies.
Drug pagePM 01183: every studyMany companies study it; this page follows only the 27 they lead. All 53 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PharmaMarits history only | 202 open or running | phase 3since Apr 10, 2015 | Apr 6, 2009 | Aug 30, 2029phase 3 · NCT06088290 |
| Jazz Pharmaceuticalsits history only | 32 open or running | phase 2since Nov 8, 2021 | Nov 8, 2021 | Jan 28, 2028phase 2 · NCT05734066 |
| Luye Pharma Groupits history only | 21 open or running | phase 3since Jul 3, 2024 | Nov 5, 2020 | Dec 31, 2027phase 3 · NCT06496048 |
| Gilead Sciencesits history only | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Rocheits history only | 11 open or running | phase 3since Oct 12, 2021 | Oct 12, 2021 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Apr 6, 2009.
- May 6, 20152 phase 2 studiesPharmaMar · NCT02454972, NCT02451007
- Sep 24, 2015Phase 3 study in Small Cell Lung CarcinomaPharmaMar · NCT02566993 · 613 enrolled · United States, Argentina, Austria and more
- Nov 5, 2015Phase 2 study in GlioblastomaPharmaMar · NCT02611024 · 316 enrolled · United States, France, Germany and more
- Nov 5, 2020Luye Pharma Group’s first study: phase 1 study in Advanced Solid TumorNew to Luye Pharma GroupLuye Pharma Group · NCT04638491 · 32 enrolled · China
- Sep 2, 20213 phase 1 studiesPharmaMar · NCT05072106, NCT05063318, NCT05101265
- Oct 12, 2021Hoffmann-La Roche’s first study: phase 3 study in Small Cell Lung CarcinomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT05091567 · 660 enrolled · United States, Belgium, Germany and more
- Nov 8, 2021Jazz Pharmaceuticals’ first study: phase 2 study in Neoplasm MetastasisNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT05126433 · 47 enrolled · United States
- Nov 29, 2021Phase 3 study in Small Cell Lung CarcinomaPharmaMar · NCT05153239 · 705 enrolled · United States, Australia, Austria and more
- Feb 2, 2023Phase 2 study in Sarcoma, EwingJazz Pharmaceuticals · NCT05734066 · 60 planned · United States, Canada
- Sep 28, 2023Phase 3 study in LeiomyosarcomaPharmaMar · NCT06088290 · 469 enrolled · United States, Austria, Belgium and more
- Jul 3, 2024Phase 3 study in Small Cell Lung CarcinomaLuye Pharma Group · NCT06496048 · 180 planned · China
- Jan 24, 2025Gilead Sciences’ first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
- Mar 5, 2026Phase 2 study in Small Cell Lung CarcinomaJazz Pharmaceuticals · NCT07459634 · 50 planned · United States
- Nov 6, 2026Primary completion moved from 2028-01-31 to 2029-08-04Date moved laterphase 2 · +18 months · NCT07459634
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaLuye Pharma Group · NCT06496048
- Jan 28, 2028Primary completion: phase 2 study in Sarcoma, EwingJazz Pharmaceuticals · NCT05734066
- Aug 4, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaJazz Pharmaceuticals · NCT07459634
- Aug 30, 2029Primary completion: phase 3 study in LeiomyosarcomaPharmaMar · NCT06088290
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07459634Small Cell Lung Carcinoma · United States | 2 | Recruiting | Jazz Pharmaceuticals | Aug 4, 2029 | 50 |
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Gilead Sciences | Oct 2029 | 695 |
| NCT06496048Small Cell Lung Carcinoma · China | 3 | Recruiting | Luye Pharma Group | Dec 31, 2027 | 180 |
| NCT06088290Leiomyosarcoma · United States, Austria, Belgium and more | 3 | Active, not recruiting | PharmaMar | Aug 30, 2029 | 469 |
| NCT05734066Sarcoma, Ewing · United States, Canada | 2 | Recruiting | Jazz Pharmaceuticals | Jan 28, 2028 | 60 |
| NCT05153239Small Cell Lung Carcinoma · United States, Australia, Austria and more | 3 | Completed | PharmaMar | Apr 10, 2026 | 705 |
| NCT05126433Neoplasm Metastasis · United States | 2 | Terminated | Jazz Pharmaceuticals | Dec 20, 2023 | 47 |
| NCT05091567Small Cell Lung Carcinoma · United States, Belgium, Germany and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jul 29, 2024 | 660 |
| NCT05101265Advanced Solid Tumor · Spain | 1 | Recruiting | PharmaMar | Jun 1, 2025 | 24 |
| NCT05072106Advanced Solid Tumor · Spain | 1 | Completed | PharmaMar | Jan 18, 2022 | 11 |
| NCT05063318Advanced Solid Tumors · Spain | 1 | Completed | PharmaMar | Apr 21, 2022 | 14 |
| NCT04638491Advanced Solid Tumor · China | 1 | Completed | Luye Pharma Group | Nov 4, 2023 | 32 |
| NCT02611024Glioblastoma · United States, France, Germany and more | 2 | Completed | PharmaMar | Jul 1, 2025 | 316 |
| NCT02566993Small Cell Lung Carcinoma · United States, Argentina, Austria and more | 3 | Completed | PharmaMar | Feb 24, 2020 | 613 |
| NCT02451007Solid Tumors · United States, Spain | 2 | Completed | PharmaMar | Aug 19, 2016 | 39 |
| NCT02454972Advanced Solid Tumors · United States, Belgium, France and more | 2 | Completed | PharmaMar | Sep 18, 2020 | 345 |
| NCT02421588Ovarian Neoplasms · United States | 3 | Completed | PharmaMar | Oct 12, 2018 | 442 |
| NCT02210364Breast Neoplasms · Belgium, Spain | 1 | Completed | PharmaMar | Oct 2016 | 81 |
| NCT01980667Neoplasms · Switzerland, United Kingdom | 1 | Completed | PharmaMar | Jan 5, 2017 | 41 |
| NCT01970553Neoplasms · Spain, United Kingdom | 1 | Completed | PharmaMar | Oct 2013 | 47 |
| NCT01970540Neuroendocrine Tumors · Spain, United Kingdom | 1 | Completed | PharmaMar | Aug 9, 2017 | 122 |
| NCT01951157Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | PharmaMar | Nov 2016 | 69 |
| NCT01831089Breast Neoplasms · United States, Spain, Switzerland | 1 | Completed | PharmaMar | Jul 2016 | 69 |
| NCT01525589Breast Neoplasms · United States, Spain | 2 | Completed | PharmaMar | Oct 2018 | 111 |
| NCT01405391Major Advanced Solid Tumors Other Than Colorectal · United States | 1 | Completed | PharmaMar | Jan 2016 | 42 |
| NCT01314599Leukemia · United States | 1 | Completed | PharmaMar | Jul 2015 | 45 |
| NCT00877474ADVANCED SOLID TUMORS · United States, Spain | 1 | Completed | PharmaMar | Jun 2011 | 30 |
How it is read
Names in the registry
- “Lurbinectedin”, 13 entries
- “lurbinectedin (PM01183)”, 6 entries
- “Lurbinectedin (PM01183)”, 3 entries
- “PM01183”, 3 entries
- “Lurbinectedin (regions/countries where approved and available)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Breast Neoplasms, 3 studies
- Neoplasms, 2 studies
- Sarcoma, Ewing, 1 study
- Leiomyosarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.